Nitric oxide synergizes minoxidil delivered by transdermal hyaluronic acid liposomes for multimodal androgenetic-alopecia therapy
Androgenetic alopecia (AGA) is a common clinical condition, affecting over 200 million people globally each year. For decades, Minoxidil (Mi) tincture has been the primary treatment for this disease, but its low utilization rate and significant side effects necessitate new therapeutic strategies. Ni...
Main Authors: | Hui Xing, Huanqi Peng, Yuhui Yang, Kai Lv, Shihao Zhou, Xiangjun Pan, Jianjin Wang, Yunfeng Hu, Guowei Li, Dong Ma |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2024-02-01
|
Series: | Bioactive Materials |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452199X23003055 |
Similar Items
-
New Target for Minoxidil in the Treatment of Androgenetic Alopecia
by: Shen Y, et al.
Published: (2023-08-01) -
The latest reports on androgenetic alopecia
by: Anna Łopuszyńska, et al.
Published: (2024-08-01) -
Evaluation of hair regrowth after minoxidil and dutasteride tattooing in men with androgenetic alopecia
by: Sara D. Ragi, MS, et al.
Published: (2023-09-01) -
Pathogenesis of androgenetic alopecia
by: Ajithkumar Kidangazhiathmana, et al.
Published: (2022-01-01) -
PHARMACOTHERAPY ALOPECIA ANDROGENETIC IN MEN
by: Riezky Januar Pramitha, et al.
Published: (2013-03-01)